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Summary We have compared the expression of insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) in ten paired samples
of normal and tumour colonic tissue with regard to both mRNA and protein. We have compared sensitivity of these tissues to IGF-I using
primary cultures of epithelial cells of colonic mucosa, and we have examined the production of IGFs and IGFBPs by these cells. In the tissues,
IGFBP-2 mRNA was expressed in all normal and cancer samples but other IGFBPs showed variable expression. mRNAs for IGF-I were
expressed in all normal and cancer tissues but IGF-11 mRNA was only detected in cancer tissue (3 out of 10). Immunostaining of sections of
normal and cancer tissue was negative for IGF-I and IGF-11; IGFBP-2 was positive in 2 out of 10 cancertissues and 7 out of 10 normal tissues;
IGFBP-3 was positive in 7 out of 10 cancer tissues and 7 out of 10 normal tissues; and IGFBP-4 was positive in 5 out of 10 cancer tissues
and 6 out of 10 normal tissues. In the cells in culture, cancer cells showed increased incorporation of [35S]methionine into protein and
[3H]thymidine into DNA (P< 0.02) when treated with IGF-I. Western blotting of serum-free conditioned media from cells in culture showed that
8 out of 10 normal and 3 out of 10 cancer cultures produced a 32-kDa immunoreactive IGFBP-2. No IGFBP-3 was secreted by any culture but
24-kDa IGFBP-4 was found in 3 out of 10 normal and 5 out of 10 cancer tissues. Because of the discrepancy between mRNA and protein
expression for IGFBP-2, degradation of native IGFBPs was assessed using tissue extracts. Colon cancer extracts were able to degrade
exogenous IGFBP-2, IGFBP-3 and IGFBP-4, whereas normal tissue extracts were without effect on IGFBP-2. We conclude that IGFBPs are
synthesized and secreted by cells of the colonic mucosa but that proteolysis of secreted IGFBP-2 occurs in colon cancertissue. This selective
degradation may confer a growth advantage.
Keywords: colonocytes; insulin-like growth factors; insulin-like growth factor binding proteins; IGFBP protease; colonic tumours; mRNA
IGF-I and -II are small polypeptides with structural homology to
pro-insulin (Daughaday and Rotwein, 1989). Circulating IGF-I is
mainly derived from the liver under the regulation of growth
hormone (GH), but many tissues secrete IGF-I and -II and are
sensitive to their autocrine actions (Humbrel, 1990). At high
concentrations, IGFs can exert acute metabolic effects via the
insulin receptor, but their predominant, long-term effects are upon
tissue growth and differentiation. IGF actions are modulated by a
family of six specific binding proteins, the IGFBPs, which may
inhibit or enhance IGF actions (Rechler, 1994). High-affinity
binding ofthe IGFs to the IGFBPs prevents receptor binding, thus
inhibiting IGF effects; however, the mechanisms responsible for
potentiation are not clear.
Overproduction of these potent growth factors has been
reported in established tumours of the breast, kidney and liver
(Reeve et al, 1985; Haselbacher et al, 1987; Foekens et al, 1989;
Singh et al, 1990) and IGFs are implicated in tumour development
(Cullen et al, 1991). Thus, in Beckwith Weidemann syndrome, in
which the IGF-II gene is effectively overexpressed, there is an
excess of tumours in childhood (Weidemann, 1983; Truleau et al,
1984). In addition, in acromegaly, in which circulating IGF levels
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are raised, there is an increased incidence of colonic polyps and
cancers and ofthyroid tumours (Ezzat, 1992; Braziley et al, 1991).
In normal colon, IGF-II mRNA is not expressed, but in cancers it
is overexpressed in one-third ofcases, suggesting thatautocrine IGF
may beimportantin tumourgrowth (Tricoli etal, 1986). Differences
between normal and neoplastic IGFBP production have not been
studied in the colon, although dysregulation of the circulating
IGFBP-2/-3 ratio has beenreported in thosewithestablishedcolonic
cancer (El Atiq etal, 1994). Expression ofIGFBP mRNA in colonic
cancer (mainly IGFBP-2 and -4), reflecting that seen in some estab-
lished colon cell lines, has been reported, but no comparisons to
normal mucosal expression have been made (Singh et al, 1995).
Specific proteases for IGFBPs have been characterized from
several tissues. Starvation induces calcium-dependent serine
proteases specific for IGFBP-2, and the degraded fragments bind
IGFs with much lower affinity (McCusker et al, 1991). There are
also specific proteases for IGFBP-3 that become activated under
stress (Davenport et al, 1992) and during pregnancy (Guidice et al,
1990), and again binding affinity is reduced by proteolysis.
Specific IGFBP-4 proteases require IGFs for activation, and
studies to date show that this proteolysis relieves the inhibitory
effects ofIGFBP-4 on IGF action (Cohick et al, 1993; Conover et
al, 1993). Proteolysis of IGFBP-5, which has been observed in
osteoblast cells, potentiates the effects of IGF-I (Andress and
Bimbaum, 1992). The fragments have been shown to have effects
independent from IGF-I (Andress et al, 1993).
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Table 1 IGF and IGFBP mRNA expression determined by Northern Blot
analysis from ten paired normal and malignant colonic mucosa specimens
IGF-I IGF-II BP-1 BP-2 BP-3 BP-4 BP-5 BP-6
Normal 10 0 0 10 3 7 3 2
Cancer 10 3 0 10 5 7 3 3
2.0 kb>
2.5 kb>
2.6 kb>
N C N C
Figure 1 IGFBP mRNA expression by normal (N) and malignant (C) colonic
mucosa was determined by Northern analysis using 32P-labelled cDNAs as
probes. Representative autoradiographs of IGFBP-2 mRNA (2.0 kb), IGFBP-
3 mRNA (2.5 kb) and IGFBP-4 mRNA (2.6 kb) are shown. Transcript sizes
were determined by comparison to rat rRNA markers (Sigma)
The aim ofthis study was to determine the role ofthe IGF axis
in colonic cancer. We examined the expression of IGFs and
IGFBPs in normal and cancerous colonic tissue by Northern and
Western blotting. We also determined the patterns of IGFBP
production by cultured normal and neoplastic epithelium obtained
from patients at operation, and in addition we have measured
cellular growth responses to IGF-1. Because we observed a reduc-
tion in the expression ofIGFBP-2 in the cancer tissues that did not
correlate with the expression of its mRNA, we examined whether
there was enhanced proteolysis ofIGFBPs in the tumours.
MATERIALS AND METHODS
Primary cultures of colonic epithelium
Primary cultures were obtained from 10 paired normal and tumour
tissues using the method described by Moyer (1983) with modifi-
cations. Cancers were all sporadic with Duke's stage B orC classi-
fication. Tissues were collected directly from the operating
theatres, rapidly dissected and thoroughly washed in Hanks'
balanced salt solution (HBSS). Using a blunt spatula, the epithe-
lium was scraped from the normal mucosa and homogenized on
ice using five up-down strokes in a Dounce glass tissue homoge-
nizer. After centrifugation at 800 r.p.m. for 5 min, the cells were
resuspended in 10% fetal bovine serum (FBS) (Gibco) in
Dulbecco's modified Eagle medium/Ham's F12 (DMEM/F12M)
1:1 (Sigma Chemical) supplemented with antibiotics (penicillin
100Uml-', gentamycin 100 ,ugml-' andmetronidazole 100 ,ugml-')
at 104 cells ml-'. Tumour tissue was finely minced with opposed
scalpels, homogenized and cultured as for the normal epithelium.
Cells were cultured in serum-supplemented media for 24 h,
during which time contaminating fibroblasts became adherent to
the culture flasks, while the epithelial and tumour cells remained
in suspension. Cells in suspension were then washed in HBSS and
maintained serum free in DMEM/F12M supplemented in anti-
biotics. Cell viability at each stage was determined by trypan blue
exlusion.
Cell morphology
Once established in serum-free conditions, cells were cytospun
onto slides, fixed with acetone and stained with Giemsa and with
cytokeratin 17 antibody using peroxidase-diaminobenzidine for
detection. Cell type and number were determined by an indepen-
dent pathologist.
Protein synthesis
After 24 h in serum, cells were washed and suspended in
DMEM:Fl2 medium containing [35S]methionine (10 ,Ci ml-',
specific activity >400 Ci mmol-'; ICN) at 104 cells ml-' for 48 h.
Cells were collected by centrifugation at 2000 r.p.m. for 20 min,
washed in HBSS and precipitated with 1 ml of ice-cold 6%
trichloroacetic acid (TCA). Precipitates were dissolved in 0.1 M
sodium hydroxide, and [35S]methionine incorporation was deter-
mined by liquid scintillation counting.
[3H]Thymidine incorporation
The effect of exogenous IGF-I (30 ng ml-') on [3H]thymidine
incorporation into TCA-precipitable material in cells cultured in
serum-free medium was determined. After 24 h in serum-free
conditions, medium was changed and cells, at 104 cells ml-', were
treated with IGF-I and [3H]thymidine (1 ,Ci ml-', specific activity
60 Ci mmol-'; Amersham). After 48 h, cells were collected by
centrifugation, and [3H]thymidine incorporation was determined
by liquid scintillation counting as described above.
IGFBP identification
Primary cultures were established in serum-free conditions at 104
cells ml' (typically 10-ml cultures were used) and after 48-h-
conditioned media were collected. Cells were removed by
centrifugation at 2000 r.p.m. for 15 min. Proteins in the super-
natants from equal cell numbers (105 cells) were precipitated
with three volumes of ethanol at -20°C for 2 h. Samples were
centrifuged for 30 min at 2000 r.p.m. and the proteins were
subjected to Western ligand analysis using ['251]IGF-II
(Amersham), as described by Baxter et al (1986). Briefly, proteins
were dissolved in loading buffer (2% sodium dodecyl sulphate
(SDS), 25% sucrose, 75 mm Tris HCl pH 6.8), heated to 100°C for
5 min and separated by electrophoresis on 12.5% SDS-polyacryl-
amide gels undernon-reducing conditions. Afterelectroblotting of
proteins onto PVDF membranes (Immobilon P, Millipore) for
3 h at 450 mA, membranes were blocked for 1 h in 15% skimmed
milk in 0.05 M phosphate buffer (pH 7.2). Membranes were
incubated for 16 h with [1251]IGF-II (2 ,Ci per 100 ml in 0.5%
albumin, 0.05 M phosphate buffer, pH 6.5) at4°C and washed four
times in phosphate buffer (0.05 M, pH 6.5). The second wash was
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IGF-I mRNA8 kb >
IGF-II mRNA6 kb >
and Professor S Shimasaki (LaJolla) respectively. Afterhybridiza-
tion at 650 C for 16 h, membranes were washed in solutions of
SDS and standard saline citrate (SSC, 10 mm sodium citrate,
150 mm sodium chloride, pH 7.0) 0.1% SDS in 2 x SSC for 30 min
at 22°C, 0.1% SDS in 0.2 x SSC for 15 min at 45°C and 0.1% SDS
in 0.2 x SSC for 15-30 min at 65°C. Bands were visualized by
autoradiography after exposure to Kodak AR film for 16 h to 5
days at-80°C.
28S rRNA >
N C N C N C
Figure 2 IGF-I and -11 mRNA expression in normal and malignant colonic
mucosa was determined by Northern analysis using 32P-labelled cDNAs.
Representative autoradiographs of three paired tissues are shown. Transcript
sizes of IGF-I mRNA (8.0 kb) and IGF-11 mRNA (6.0 kb) were determined by
comparison to rat rRNA markers
Table 2 Immunoreactive IGFBP expression by formaldehyde-fixed colonic
mucosa determined by immunohistochemistry using specific antisera to
IGFBP-2, -3 and -4
IGFBP-2 IGFBP-3 IGFBP-4
Normal 7 7 6
Cancer 2 7 5
Primary antibody binding was detected by the ABC procedure (Vector
Laboratories). Ten paired samples were used.
supplemented with 0.1% Nonidet P40. ['251]IGF-II binding was
determined by autoradiography using Kodak AR film for 16 h
with Cronex image intensifying screens (Du Pont) at-800C.
Subsequent to Western ligand blot analysis, membranes were
probed with antibodies to IGFBP-2, -3 and -4 (TCS). Membranes
were reblocked, washed in phosphate-buffered saline (PBS, 10 mM
sodium phosphate, 150 mm sodium chloride, pH 7.0) for 30 min and
incubated with 1:500 dilution of primary antibody for 1 h. After a
second PBS wash, membranes were incubated with horseradish
peroxidase-linked anti-rabbit IgG secondary antibody (1:75 000
dilution, Amersham) for 1 h. Antibody binding was visualized using
the Amersham Enhanced Chemiluminesence System (ECL).
Northern blot analysis
Ten paired samples of normal and neoplastic tissue were studied.
Freshly collected tissues (whole bowel) were rapidly frozen in
liquid nitrogen, and total RNA was extracted using the single-step
method (Chomczynski and Sacchi, 1987). RNA purity was deter-
mined by its 260:280 nm absorbance ratio and quantified by its
absorbance at 260 nm. Thirty micrograms ofRNA were separated
on a denaturing (18.5% formaldehyde) 1% agarose gel (100 V for
3 h) and transferred by capillary action over 16 h onto nylon
membranes (Zetaprobe, BioRad). Membranes were blocked for
5 min in 7% SDS in 0.5 M phosphate buffer (pH 7.2) at 65°C. 32p_
labelled cDNAs for IGF-I and II, and IGFBPs 1-6 were synthe-
sized by random primer extension using a commercially available
kit (Oligolabeling kit, Pharmacia). Template cDNAs for the IGFs
and IGFBPs were kindly provided by Professor GI Bell (Chicago)
Immunohistochemistry
Ten paired samples were used. Tissue was formalin fixed,
embedded in wax, sectioned and mounted. Sections were dewaxed
by washing in xylene and rehydrated by sequential ethanol washes
(10 min each in 100%, 90%, 80%, 60% and 50% ethanol).
Endogenous peroxidase activity was inhibited by incubation with
methanol/0.01% hydrogen peroxide for 30 min. Sections were
blocked for 1 h at room temperature with 5% albumin. Primary
antibodies to IGF-I (NIH) and -II (Gro-pep) and IGFBPs 2-4
(Upstate Biologicals) were diluted 1:500 with PBS and incubated
with sections for 1 h at room temperature. Slides were thoroughly
washed and secondary antibody was added for 30 min. Following
a 30-min PBS wash, antibody binding was visualized using
the avidin-biotin complex system (Vectastain). Sections were
counterstained with Meyer's haematoxylin. Immunoreactivity was
independently scored.
IGFBP protease activity
Fifty-milligram samples of frozen tissue (normal and tumours)
were rapidly homogenized in HBSS in a Class II containment
cabinet using a mechanical homogenizer and were analysed for
IGFBP content and protease activity. IGFBP content of 5-ml
homogenates were determined by Western ligand analysis.
Proteins were precipitated under three volumes of ethanol at
-20°C for 2 h and pelleted by centrifugation at 2000 r.p.m. for
30 min. The IGFBP content was determined by Western ligand
analysis as described above. IGFBP protease activity in these
homogenates was determined by adding known IGFBPs to these
homogenates and following their degradation. We have previously
found that two human cell lines derived from pancreatic cancer
produce large amounts of IGFBPs. BxPc-3 and SUIT-2 cell-
conditioned medium were used as the source of IGFBP-2, -4 and
IGFBP-3, -4 respectively. IGFBPs were derived from single
cultures of these serum-free cell lines to ensure consistency of
binding protein type and concentration. Five-millilitre aliquots
from each homogenized sample were incubated with IGFBP-2 and
-4 or IGFBP-3 and -4 for 1 h at 37°C. Control incubations of
BxPc-3 and SUIT-2 cell-conditioned medium without homogenate
were run in parallel to control for endogenous proteolysis of the
IGFBPs. The effect of heating each sample to 100°C for 5 min
before IGFBPaddition was also determined. Following co-incuba-
tions, IGFBPs were precipitated under three volumes of ethanol
and identified by Western ligand analysis.
RESULTS
IGFBP mRNA expression in normal and cancer tissues
Table 1 shows data for IGFBP mRNA expression in normal and
cancer tissues. Representative blots of transcripts for IGFBP-2
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Figure 3 Purified normal (A) and neoplastic (B) colonocytes were fixed and stained after 24 h in culture. Cell type was determined by morphology after staining
with Giemsa stain (left) with anti-cytokeratin 17 antibody (right)
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Table 3 The effects of IGF-I (30 ng ml-') on a 48-h incorporation of [35S]methionine and [3H]thymidine into
cells in primary culture from four paired samples, expressed as fold increase of control values
Normal Cancer
Sample 35S]methionine [3H]thymidine [35S]methionine [3H]thymidine
1 1.21 * 0.9* 1.35 1.8
2 1.26 1.3* 1.88 1.9
3 1.31 1.1* 2.09 2.1
4 1.24 1.1* 5.96 3.4
*P not significant, otherwise P< 0.05.
IGFBP-2 32 kDa> .. *-_l
+ N C N C N C N C
Figure 4 IGFBP-2 secretion into 48-h serum-free cell-conditioned media was
determined by Western analysis using enhanced chemiluminescence
detection. Data from four paired samples are shown. N, normal colonocytes;
C, cancer colonocytes. Lane + represents the positive control IGFBP-2 from
the BxPc-3 cell line. Molecular weights were determined by comparison to M
markers (Sigma)
Table 4 Immunoreactive IGFBPs secreted into 48-h cell-conditioned media
were determined by Western analysis using specific antisera to IGFBP-2,
-3 and -4 and the ECL detection system (Amersham). Ten paired samples
were used
IGFBP-2 IGFBP-3 IGFBP-4
Normal 8 0 3
Cancer 3 0 5
(2.0 kb), IGFBP-3 (2.5 kb) and IGFBP-4 (2.6 kb) are shown in
Figure 1. IGFBP-2 mRNA was uniformly expressed by normal
and cancer tissues (1O out of 10). IGFBP-3 mRNA was detected in
3 out of 10 normal colonic epithelium specimens and in 5 out of 10
cancer specimens. IGFBP-4 mRNA was detected in 7 out of 10
normal and 7 out of 10 cancer specimens. IGFBP-5 mRNA was
expressed in 3 out of 10 normal and 3 out of 10 cancer specimens
and IGFBP-6 mRNA by 2 out of 10 normal and 3 out of 10 cancer
tissues. IGFBP-l mRNA was not detected in any sample.
IGF-I and -11 mRNA expression
Figure 2 shows IGF-I and -II mRNA expression by Northern
analysis in three paired samples of normal and cancer tissue. Ten
paired samples were analysed in total and the data are shown in
Table 1. All normal and colonic cancer tissues expressed IGF-I
mRNA. The absolute amount of 8.0-kB IGF-I mRNA relative to
rRNA varied considerably both between the normal tissues and
their tumour counterparts, and no consistent quantitative differ-
ences were observed. In Figure 2, the cancer tissue shown in lane
3, which shows strong IGF-II mRNA labelling, was also positive
for IGF-I on longer exposure. IGF-II mRNA was expressed by 3
out of 10 cancers but was not detected in normal tissue.
Immunohistochemistry
The results ofimmunostaining forthe IGFs and IGFBPs are shown
in Table 2. No IGF-I or-II could be detected in any sample. This
may be because of the loss of IGFs during tissue fixation or
because of the loss of immunoreactivity. Staining for IGFBP-2
was observed in 7 out of 10 normal samples and in 2 out of 10
cancer samples. Positive IGFBP-3 staining was seen in 7 out of 10
normal and 7 out of 10 cancer specimens, and IGFBP-4 staining
was seen in 6 out of 10 normal and 5 out of 10 cancer samples. In
all cases, immunoreactivity was confined to the epithelial and
cancer cells.
Primary culture characterization
Purified colonocytes were confirmed as normal epithelial or
tumour cells by Giemsa and cytokeratin 17 staining (Figure 3).
Less than 5% were contaminating fibroblasts. Maintenance of
differentiation was confirmed by induction of mRNA for 24-
hydroxylase with vitamin D3 treatment (Kane et al, 1994).
Protein synthesis and DNA synthesis
[35S]methionine incorporation ofpaired normal and cancercolono-
cytes cultured in serum-free medium after stimulation with IGF-I
(30 ng ml-1) for 48 h was determined. The experiment was
repeated four times with triplicate samples. Sodium azide (0.1%),
a cytotoxic agent, was added to some cultures to control for non-
specific radioactivity. The data are shown in Table 3. Basal incor-
poration by normal cells was increased after a 48-h treatment with
30 ng ml-' IGF-I in three of four experiments. Colon cancer cells
showed a more pronounced increase in [35S]methionine incorpora-
tion after IGF-I treatment.
The effect of IGF-I on 48-h [3H]thymidine incorporation in
paired normal and cancercolonocytes is shown in Table 3. We have
not pooled the data from the experiments because of the inherent
variability of primary cultures. In the normal cells, there was no
significant increase in incorporation after treatment with 30 ng ml-'
IGF-I in any of the experiments, whereas the incorporation of
[3H]thymidine was significantly increased by 30 ng ml-' IGF-I in
all experiments with the colonocytes derived from the tumours.
IGFBP secreted from cells in culture
Westem blots
Figure 4 shows the results ofWestem blotting for IGFBP-2 in four
paired samples from normal and cancer colonocytes and Table 4
summarizes the data obtained with IGFBP-2, -3 and -4 antisera
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IGFBP-2 32kDa 4
+ C ..C* N N
Figure 5 Western ligand blot showing the effects of tissue homogenates
from normal (N) and malignant (C) mucosa on exogenous IGFBPs. Tissues
(50 mg) were homogenized and incubated with IGFBP-2, -3 and -4 from
pancreatic cancer cell lines BxPc-3 and SUIT-2. Those marked with a
asterish were heated to 1000C before IGFBP addition
with ten paired samples. Eight of ten normal cultures produced a
32-kDa immunoreactive IGFBP-2 compared with 3/10 cancer
cultures. In the cancer tissues shown in Figure 4, no immunoreac-
tivity was found in three of the samples. In the normal tissues, 32-
kDa IGFBP-2 is seen in three of four samples and in two, a
discrete degradation product is seen. Immunoreactive 24-kDa
IGFBP-4 was secreted into the conditioned media of 5 out of 10
cancers and 3 out of 10 normal epithelial cell cultures. No
immunoreactive IGFBP-3 was found in any of the 10 primary cell
culture media examined.
Westem ligandblots
Western ligand blots ofsecreted IGFBPs gave variable results. The
immunoreactive IGFBP-2 bound ligand in 2 out of 10 normal
colonocyte cultures and 3 out of 10 neoplastic colonocyte cultures.
The immunoreactive IGFBP-4 bound ligand in 2 out of 10
neoplastic but none of the normal colonocyte cultures. No other
bands were detected by Western ligand analysis.
IGFBP protease activity
No IGFBPs could be detected in tissue extracts from normal or
cancer tissue using Western ligand analysis. Figure 5 of a Western
ligand blot shows the effects of incubating tissue homogenates
with exogenous IGFBP-2, -3 and -4. The endogenous proteolysis
of the samples of native IGFBPs used for substrate in these assays
showed negligible proteolysis during the 1-h incubation (lane +).
Cancer tissues completely degraded exogenous IGFBPs after a 1-h
incubation. This was prevented by heat-treating the tissue extract
to 100°C before co-incubation. Normal tissue extracts degraded
exogenous IGFBP-3 and -4 in all cases (n = 7), these effects being
reduced by heat treatment. In five of seven samples, exogenous
IGFBP-2 remained intact after a 1-h co-incubation with normal
tissue extracts.
DISCUSSION
The primary culture system used in this study, using cells obtained
from individual patients, provided a more credible system for
studying the IGFs and IGFBPs synthesized by colonic mucosa
than established cell lines with their potential for genetic changes
with multiple passages. Primary cultures of cells were capable of
protein and DNA synthesis; staining confirmed that epithelial cells
formed the majority of those present; and induction of expression
of mRNA for 24-hydroxylase (Kane et al, 1994), in response to
vitamin D, indicated that cells remained functional. We were able
to maintain viable cells in serum-free media, which allowed
analyses of secreted proteins.
Cancer cells in culture responded to exogenous IGF-I at physio-
logical concentrations by increasing protein and DNA synthesis
twofold above control levels. Normal cells were less responsive
but did show basal levels of protein and DNA synthesis. The
poorer response of normal cells may reflect the presence of
specific inhibitors, such as binding proteins or proteases rather
than inadequate IGF receptor expression, because IGF binding has
been demonstrated in normal epithelium (Guo et al, 1992).
All tissues, neoplastic or not, expressed IGF-I mRNA but no
normal tissue expressed IGF-II mRNA. In 3 of 10 tumours, IGF-II
mRNA was detected, consistent with the study of Tricoli et al
(1986). As IGF-II mRNA synthesis has been shown to correlate
with protein synthesis in colonic cancer (Lambert et al, 1990), it is
possible that IGF-II is acting as an autonomous growth factor in a
significant proportion ofcolonic cancer cases. Our failure to detect
IGFs on the tissue sections may be loss ofthese small polypeptides
during fixing and washing or because oftheir proteolysis.
IGFBP mRNA expression did not differ materially between
normal and malignant colonic tissue, IGFBP-2 being present in all
samples, IGFBP-4 being detected frequently and IGFBP-3, -5 and
-6 less often. Although these assessments were not quantitative,
the universal detection of IGFBP-2 mRNA confirms the integrity
of the mRNA, and the negative data with some samples are thus
likely to be real. Low levels of mRNA may however not be
detected.
Western analyses using the primary cultures of colonocytes
showed that IGFBPs were less often detectable than their corre-
sponding mRNAs in the tissue. Western ligand blots showed fewer
positive samples than the antibody blots, although the antibody
blots showed ostensibly intact IGFBP-2. Whether there is limited
proteolysis occurring in a step-wise fashion from the N- or C-
terminus ofthe IGFBP, which renders it incapable ofbinding IGF
on a ligand blot, is a possibility. Immunoreactive IGFBP-2 was
consistently detected in the conditioned medium and tissue
sections from normal colonic epithelial cells but not in those from
cancers. As the cancer tissue expresses the mRNA for IGFBP-2,
the loss of IGFBP-2 in the conditioned medium again implicates
proteolysis.
IGFBP proteases have been detected for IGFBP-3 in prostatic
cancer (Cohen et al, 1994) and IGFBP-4 in osteoblast cell systems
(Lalou et al, 1994). A serine protease that specifically degrades
IGFBP-5 in fibroblasts has been reported (Nam et al, 1994). In
pregnancy, a serum protease exists that degrades IGFBP-3
(Giudice et al, 1990). In all of these conditions, IGFBP degrada-
tion, specific or general, resulted in enhanced IGF activity, and
dysregulation of this process may promote autonomous growth.
There have been no reports ofthe presence ofIGFBP proteases or
their inhibitors in the colon.
In our degradation studies, we used native glycosylated human
IGFBPs as substrates rather than recombinant, radiolabelled
IGFBPs because of the possibility that specific IGFBP proteases
may require IGFBPs of the same species of origin and of native
conformation. IGFBP-4 is degraded by both the normal and the
cancer tissue extracts. There is however no difference between the
normal and the cancer tissue in this regard, and in the immuno-
staining experiments there is no marked difference in the expres-
sion of IGFBP-4 in vivo Our consistent detection of mRNA for
IGFBP-3 and the identification of immunoreactive IGFBP-3 in
tissue sections, but not in cell-conditioned media, may indicate
that this IGFBP-3 is made locally by other cell types in the tissue.
Alternatively, IGFBP-3 may not be secreted or may be degraded
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rapidly. The immunostaining data would argue against the latter
interpretation because most normal and cancer tissues express
immunoreactive IGFBP-3.
In contrast to the data with IGFBP-3 and IGFBP-4, IGFBP-2
was degraded by extracts of colonic tumour tissue but not normal
tissue. Our data with IGFBP-2 imply that in the normal tissue
IGFBP-2 is protected or that in the tumour tissues there is a
protease specific for IGFBP-2. We have reported elsewhere
(Michell et al, 1995) that IGFBP-2 can inhibit IGF-I-induced cell
growth and loss ofthis IGFBP could give cancerous cells a growth
advantage. The loss ofIGFBP-2 in the cancer tissues was also seen
in the immunostained sections from patients for whom 7 out of 10
normal samples showed positive immunoreactivity compared with
2 out of 10 from the colon tumours. These data indicate that
IGFBP-2 is degraded by the tumours in vivo.
Our findings of decreased IGFBP-2 secretion by cancers
contrasts with the suggestion that serum levels ofIGFBP-2 may be
elevated in cancer patients (El Atiq et al, 1994). However, circu-
lating IGFBPs, like circulating IGFs, are likely to originate from
the liver, and they may not be important in modulating the
autocrine effects of IGFs at the tissue.
We conclude that malignant colonocytes both respond to IGFs
and produce IGFBPs. Resistance of normal colonocytes to IGFs
may be due to the secretion of inhibitory IGFBP-2, which appears
to be protected from proteolysis. IGFBP-2 is degraded by cancer
cells, which may confer a growth advantage.
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